The 9th meeting of the European Forum on Antiphospholipid Antibodies (Euro aPL Forum) was held in Krakow, Poland, on 16–18 May 2013. This was an excellent occasion for the exchange of information on current research in the area of antiphospholipid syndrome (APS), as well as a starting point for many new research projects. About 120 physicians and researchers from various medical specialities representing 15 European countries, USA, Argentina and Israel attended the event. This report summarizes the major studies and new research projects presented during the Forum.
JamrozikJJankowskiMPartykaLSkowiniakASwadzbaJ. Lupus anticoagulant - tajemniczy prokoagulant. Pol Arch Med Wewn1993; 90: 348–355.
2.
MusiałJSwadzbaJJankowskiMGrzywaczMBazan-SochaSSzczeklikA. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost1997; 78: 1173–1177.
3.
SwadzbaJDe ClerckLSStevensWJ. Anticardiolipin, anti-β2 glycoprotein-1, anti-prothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol1997; 24: 1710–1715.
4.
SwadzbaJIwaniecTMusialJ. Increased level of tumour necrosis factor-α in patients with antiphospholipid syndrome – marker not only of inflammation but also of the prothrombotic state. Rheumatol Int2011; 31: 307–313.
5.
CerveraRBoffaMCKhamashtaMAHughesGRV. The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus2009; 18: 889–893.
6.
CerveraRKhamashtaMAShoenfeldY. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis2009; 68: 1428–1432.
7.
De LaatBVan BerkelMUrbanusRT. Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011; 63: 3960–3968.
8.
ErkanDLockshinetMD. APS ACTION – AntiPhospholipid Syndrome Alliance For Clinical Trials and International Networking. Lupus2012; 21: 695–698.
9.
PierangeliSSFavaloroEJLakosG. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta2012; 413: 358–360.
10.
PengoVTripodiAReberG. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost2009; 7: 1737–1740.
11.
DevreeseKM. Standardization of antiphospholipid antibody assays.. Where do we stand?Lupus2012; 21: 718–721.
12.
De LaatHBDerksenRHWMUrbanusRTRoestMDe GrootPG. 2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood2004; 104: 3598–3602.
13.
De LaatBDerksenRHWMReberG. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-β2-glycoprotein autoantibodies. J Thromb Haemost2011; 9: 149–153.
14.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
15.
PengoVRuffattiALegnaniC. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: A multicenter prospective study. Blood2011; 118: 4714–4718.
16.
Alarcón-SegoviaDPérez-VázquezMEVillaARDrenkardCCabiedesJ. Semin Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Arthritis Rheum1992; 21: 275–286.
17.
Alijotas-ReigJFerrer-OliverasR. EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A preliminary first year report. Lupus2012; 21: 766–768.
18.
SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology2013; 52: 1397–1403.
19.
SciasciaSMurruVSannaGRoccatelloDKhamashtaMABertolacciniML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: Evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost2012; 10: 2512–2518.
20.
VikerforsAJohanssonABGustafssonJT. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: Evaluation of two diagnostic assays. Rheumatology2013; 52: 501–509.
21.
SwadzbaJIwaniecTSzczeklikAMusiałJ. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost2007; 5: 1883–1889.
22.
SwadzbaJIwaniecTPulkaMDe LaatBDe GrootPGMusialJ. Lupus anticoagulant: Performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost2011; 9: 1776–1783.
23.
RuffattiATonelloMVisentinMS. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: A multicentre, case-control study. Rheumatology2011; 50: 1684–1689.
24.
MeroniPLBorghiMORaschiETedescoF. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol2011; 7: 330–339.
25.
MullaMJBrosensJJChamleyLW. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol2009; 62: 96–111.
26.
De CarolisSBottaASantucciS. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus2012; 21: 776–778.
27.
ReggiaRZiglioliTAndreoliL. Primary anti-phospholipid syndrome: Any role for serum complement levels in predicting pregnancy complications?Rheumatology2012; 51: 2186–2190.
28.
Alijotas-ReigJ. Treatment of refractory obstetric antiphospholipid syndrome: The state of the art and new trends in the therapeutic management. Lupus2013; 22: 6–17.
29.
AvcinTCimazRRozmanB. The Ped-APS Registry: The antiphospholipid syndrome in childhood. Lupus2009; 18: 894–899.
30.
Agmon-LevinNBlankMZandman-GoddardG. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis2011; 70: 145–150.
31.
PlazakWGrygaKMilewskiM. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus2011; 20: 936–944.
32.
ČučnikSKvederTUlcova-GallovaZ. The avidity of anti-β2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: A collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus2011; 20: 1166–1171.
33.
ČučnikSKvederTArtenjakA. Avidity of anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus2012; 21: 764–765.
34.
Celińska-LöwenhoffMIwaniecTPadjasAMusialJUndasA. Fibrin clot properties in patients with antiphospholipid syndrome. J Thromb Haemost2013; 11: 1–1322.
35.
Zuily S, Regnault V, Guillemin F, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013; 132: e1–e7.
36.
LinFMurphyRWhiteB. Circulating levels of β2-glycoprotein I in thrombotic disorders and in inflammation. Lupus2006; 15: 87–93.
37.
AndreoliLNalliCMottaM. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their ‘innocent' profile?Ann Rheum Dis2011; 70: 380–383.
38.
Ruiz-IrastorzaGCuadradoMJRuiz-ArruzaI. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus2011; 20: 206–218.
39.
ErkanDHarrisonMJLevyR. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum2007; 56: 2382–2391.
40.
EspinolaRGPierangeliSSGharaviAEHarrisEN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost2002; 87: 518–522.
41.
RandJHWuXXQuinnAS. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood2010; 115: 2292–2299.
42.
BroderAPuttermanC. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol2013; 40: 30–33.
